104 related articles for article (PubMed ID: 20959346)
1. Focal segmental glomerulosclerosis as a complication of hepatitis B virus infection.
Sakai K; Morito N; Usui J; Hagiwara M; Hiwatashi A; Fukuda K; Nanmoku T; Toda T; Matsui N; Nagata M; Yamagata K
Nephrol Dial Transplant; 2011 Jan; 26(1):371-3. PubMed ID: 20959346
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B complicated focal segmental glomerulosclerosis.
Sakallioglu O; Gok F; Kalman S; Kurekci AE; Gunhan O; Gokcay E
J Nephrol; 2005; 18(4):433-5. PubMed ID: 16245249
[TBL] [Abstract][Full Text] [Related]
3. [Application of serum hepatitis B virus large surface protein determination in lamivudine anti-viral therapy for patients with hepatitis B].
Li GY; Sheng JL; Huang HJ
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):133-5. PubMed ID: 18574538
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation.
Ben-Ari Z; Zemel R; Kazetsker A; Fraser G; Tur-Kaspa R
Am J Gastroenterol; 1999 Mar; 94(3):663-7. PubMed ID: 10086648
[TBL] [Abstract][Full Text] [Related]
5. Occult hepatitis B virus infection and lamivudine-resistant mutations in isolates from renal patients undergoing hemodialysis.
Motta JS; Mello FC; Lago BV; Perez RM; Gomes SA; Figueiredo FF
J Gastroenterol Hepatol; 2010 Jan; 25(1):101-6. PubMed ID: 19817965
[TBL] [Abstract][Full Text] [Related]
6. The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents.
Ilan E; Burakova T; Dagan S; Nussbaum O; Lubin I; Eren R; Ben-Moshe O; Arazi J; Berr S; Neville L; Yuen L; Mansour TS; Gillard J; Eid A; Jurim O; Shouval D; Reisner Y; Galun E
Hepatology; 1999 Feb; 29(2):553-62. PubMed ID: 9918935
[TBL] [Abstract][Full Text] [Related]
7. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.
Cacciola I; Pollicino T; Squadrito G; Cerenzia G; Orlando ME; Raimondo G
N Engl J Med; 1999 Jul; 341(1):22-6. PubMed ID: 10387938
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus.
Tamori A; Nishiguchi S; Shiomi S; Hayashi T; Kobayashi S; Habu D; Takeda T; Seki S; Hirohashi K; Tanaka H; Kubo S
Am J Gastroenterol; 2005 Aug; 100(8):1748-53. PubMed ID: 16086711
[TBL] [Abstract][Full Text] [Related]
9. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy.
Filippini P; Coppola N; Pisapia R; Scolastico C; Marrocco C; Zaccariello A; Nacca C; Sagnelli C; De Stefano G; Ferraro T; De Stefano C; Sagnelli E
AIDS; 2006 Jun; 20(9):1253-60. PubMed ID: 16816553
[TBL] [Abstract][Full Text] [Related]
10. Low level hepatitis B viremia detected by polymerase chain reaction accompanies the absence of HBe antigenemia and hepatitis in hepatitis B virus carriers.
Niitsuma H; Ishii M; Miura M; Kobayashi K; Toyota T
Am J Gastroenterol; 1997 Jan; 92(1):119-23. PubMed ID: 8995950
[TBL] [Abstract][Full Text] [Related]
11. Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen.
Petit MA; Buffello-Le Guillou D; Roche B; Dussaix E; Duclos-Vallée JC; Féray C; Samuel D
J Med Virol; 2001 Nov; 65(3):493-504. PubMed ID: 11596084
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ
J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
[TBL] [Abstract][Full Text] [Related]
13. Evolution of multi-drug resistant hepatitis B virus during sequential therapy.
Yim HJ; Hussain M; Liu Y; Wong SN; Fung SK; Lok AS
Hepatology; 2006 Sep; 44(3):703-12. PubMed ID: 16941700
[TBL] [Abstract][Full Text] [Related]
14. [Genotyping of hepatitis B virus and clinical investigation].
Wang Y; Zhou G; Li X; Zhou Z; Zhou S; Ruan L; Chen M; Deng W
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Dec; 16(4):367-9. PubMed ID: 12665908
[TBL] [Abstract][Full Text] [Related]
15. [Detection of peripheral blood HBV-LHBs transactivation function and its relationship with anti-viral efficacy].
Xu AF; Chen G; Wang MC; Sui DM; Zhu XY; Shi JP; Zhang YL; Lou GQ
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Oct; 23(5):375-7. PubMed ID: 20387491
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role.
Steinberg JL; Yeo W; Zhong S; Chan JY; Tam JS; Chan PK; Leung NW; Johnson PJ
J Med Virol; 2000 Mar; 60(3):249-55. PubMed ID: 10630955
[TBL] [Abstract][Full Text] [Related]
17. Genotype mixtures of hepatitis B virus in patients treated with interferon.
Hannoun C; Krogsgaard K; Horal P; Lindh M;
J Infect Dis; 2002 Sep; 186(6):752-9. PubMed ID: 12198608
[TBL] [Abstract][Full Text] [Related]
18. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.
Ben-Ari Z; Mor E; Shapira Z; Tur-Kaspa R
Liver Transpl; 2001 Feb; 7(2):113-7. PubMed ID: 11172394
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B infection of the liver in chronic hepatitis C without detectable hepatitis B virus DNA in serum.
Mariscal LF; Rodríguez-Iñigo E; Bartolomé J; Castillo I; Ortiz-Movilla N; Navacerrada C; Pardo M; Pérez-Mota A; Graus J; Carreño V
J Med Virol; 2004 Jun; 73(2):177-86. PubMed ID: 15122790
[TBL] [Abstract][Full Text] [Related]
20. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy.
Hui CK; Cheung WW; Zhang HY; Au WY; Yueng YH; Leung AY; Leung N; Luk JM; Lie AK; Kwong YL; Liang R; Lau GK
Gastroenterology; 2006 Jul; 131(1):59-68. PubMed ID: 16831590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
